Pooled Antipsychotic Data Will Be Mined For Early Response Signals
A consortium of international drug companies hopes to leverage their pooled schizophrenia data into a means of determining which patient subgroups are most likely to respond to treatment during clinical trials.
You may also be interested in...
UK-based Convergence's lead asset starts Phase II in neuropathic pain
Medco will launch a research project in November that aims to validate a biomarker that may improve the cost effectiveness of atypical antipsychotics. The pharmacy benefit manager announced a research collaboration with development-stage genetic test developer SureGene on Aug. 24
FDA's review of the pharmacogenetic data in Vanda's NDA for Fanapt (iloperidone) suggests that sponsors should be prepared for the agency to require significant clinical evaluation before including pharmacogenetic criteria in labeling